Stocks › RLMD

RELMADA THERAPEUTICS, INC.

RLMD·Nasdaq·United States United States·USD
$2.62
-0.49 (-15.76%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
RLMD
RELMADA THERAPEUTICS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
RLMDS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of RLMD by members of U.S. Congress · 2 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Christopher L. JacobsChristopher L. JacobsHouse · R · NY RLMDRELMADA THERAPEUTICS, INC. · Stock Sale
$1,001 - $15,000
Jan 20, 2023 Dec 12, 2022 Filing ↗
Christopher L. JacobsChristopher L. JacobsHouse · R · NY RLMDRELMADA THERAPEUTICS, INC. · Stock Purchase
$1,001 - $15,000
Dec 12, 2022 Nov 8, 2022 Filing ↗

Whale Activity

Position changes in RLMD reported for 2026-09-30 by 147 institutional filers
Increased: 51New: 20Held: 25Decreased: 34Closed: 12No prior filing: 5
  • Increased51
  • New20
  • Held25
  • Decreased34
  • Closed12
  • No prior filing5
FilerSharesValueChange
Janus Henderson Group Ltd.11.2M$42.0M—
BlackRock, Inc.7.6M$28.6Mincreased
Venrock Adviser, LLC7.4M$28.1Mincreased
Spruce Street Capital LP6.9M$26.1Mincreased
Jones Hill Capital LP5.2M$19.7Mincreased
ADAGE CAPITAL PARTNERS GP, L.L.C.4.8M$18.0Mheld
VANGUARD CAPITAL MANAGEMENT LLC4.4M$16.4Mdecreased
AMERIPRISE FINANCIAL INC3.7M$14.0M—
Sio Capital Management, LLC3.6M$13.7Mincreased
Squadron Capital Management LLC3.5M$13.2Mdecreased
MILLENNIUM MANAGEMENT LLC3.3M$12.6Mincreased
STATE STREET CORP3.3M$12.5Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by RLMD insiders, by quarter · Form 4
-2.0M-1.0M01.0M2.0M2025 Q1: 02025 Q12025 Q2: 979.0K2025 Q22025 Q3: 266.0K2025 Q32025 Q4: 1.0M2025 Q42026 Q1: 02026 Q12026 Q2: 02026 Q22026 Q3: 400.0K2026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

227 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Shenouda MagedChief Financial Officer Purchase +79.8K $4.25 $339K Sep 10, 2026 Form 4 ↗
TRAVERSA SERGIOChief Executive Officer · Director Purchase +100.0K $4.10 $410K Sep 10, 2026 Form 4 ↗
Shenouda MagedChief Financial Officer Purchase +120.2K $4.20 $505K Sep 9, 2026 Form 4 ↗
TRAVERSA SERGIOChief Executive Officer · Director Purchase +100.0K $4.18 $418K Sep 9, 2026 Form 4 ↗
TRAVERSA SERGIOChief Executive Officer · Director Purchase +27.5K $4.12 $113K Dec 15, 2025 Form 4 ↗
Shenouda MagedChief Financial Officer Purchase +11.7K $4.12 $48K Dec 15, 2025 Form 4 ↗
Ence ChuckCAO and COO Purchase +136.0K $2.20 $299K Nov 5, 2025 Form 4 ↗
TRAVERSA SERGIOChief Executive Officer · Director Purchase +272.5K $2.20 $600K Nov 5, 2025 Form 4 ↗
Shenouda MagedChief Financial Officer Purchase +500.0K $2.20 $1.1M Nov 5, 2025 Form 4 ↗
Kelly Paul EdwardChief Operating Officer · Director Purchase +90.0K $2.20 $198K Nov 5, 2025 Form 4 ↗
TRAVERSA SERGIOChief Executive Officer · Director Purchase +56.0K $0.74 $41K Aug 28, 2025 Form 4 ↗
TRAVERSA SERGIOChief Executive Officer · Director Purchase +129.5K $0.67 $87K Aug 27, 2025 Form 4 ↗
TRAVERSA SERGIOChief Executive Officer · Director Purchase +80.5K $0.62 $50K Aug 26, 2025 Form 4 ↗
Shenouda MagedChief Financial Officer Purchase +60.0K $0.52 $31K May 20, 2025 Form 4 ↗
TRAVERSA SERGIOChief Executive Officer · Director Purchase +147.7K $0.56 $83K May 20, 2025 Form 4 ↗
Shenouda MagedChief Financial Officer Purchase +90.0K $0.49 $44K May 19, 2025 Form 4 ↗
TRAVERSA SERGIOChief Executive Officer · Director Purchase +30.0K $0.50 $15K May 19, 2025 Form 4 ↗
Kelly Paul EdwardChief Operating Officer · Director Purchase +200.0K $0.43 $86K May 16, 2025 Form 4 ↗
Shenouda MagedChief Financial Officer Purchase +50.0K $0.44 $22K May 16, 2025 Form 4 ↗
Ence ChuckCA and CO Purchase +229.0K $0.45 $103K May 16, 2025 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding RLMD · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
3.2M$21.9M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
2.1M$14.4M0.02%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.2M$8.3M0.01%Jun 30, 2026
Eventide Healthcare & Life Sciences Fund
MUTUAL FUND SERIES TRUST
1.0M$7.0M0.39%Jun 30, 2026
iShares Russell 2000 Growth ETF
iShares Trust
865.6K$6.0M0.04%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
1.0M$5.5M0.02%Jul 31, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
SPDR SERIES TRUST
655.1K$4.5M1.06%Jun 30, 2026
Franklin Biotechnology Discovery Fund
Franklin Strategic Series
788.7K$4.2M0.36%Jul 31, 2026
AdvisorShares Psychedelics ETF
AdvisorShares Trust
438.9K$3.0M6.84%Jun 30, 2026
VANGUARD RUSSELL 2000 INDEX FUND
VANGUARD SCOTTSDALE FUNDS
541.6K$2.4M0.01%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list RLMD's shares (CUSIP 75955J402), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • William BlankSCHEDULE 13G/A · passive (13G) · 3.5M shares3.3%
    Nov 16, 2026 · ↗
  • Matthew SesterhennSCHEDULE 13G/A · passive (13G) · 3.5M shares3.3%
    Nov 16, 2026 · ↗
  • Squadron Capital Management LLCSCHEDULE 13G/A · passive (13G) · 3.5M shares3.3%
    Nov 16, 2026 · ↗
  • Squadron Master Fund LPSCHEDULE 13G/A · passive (13G) · 3.5M shares3.3%
    Nov 16, 2026 · ↗
  • William BlankSCHEDULE 13G/A · passive (13G) · 7.3M shares7.0%
    Aug 14, 2026 · ↗
  • Matthew SesterhennSCHEDULE 13G/A · passive (13G) · 7.3M shares7.0%
    Aug 14, 2026 · ↗
  • Squadron Capital Management LLCSCHEDULE 13G/A · passive (13G) · 7.3M shares7.0%
    Aug 14, 2026 · ↗
  • Squadron Master Fund LPSCHEDULE 13G/A · passive (13G) · 7.3M shares7.0%
    Aug 14, 2026 · ↗
  • BlackRock, Inc.SCHEDULE 13G · passive (13G) · 7.4M shares7.0%
    Jul 29, 2026 · ↗
  • Israel A. EnglanderSCHEDULE 13G · passive (13G) · 4.6M shares4.4%
    Jun 22, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming relmada therapeutics as client

No lobbying filings found naming RELMADA THERAPEUTICS, INC. as the client.

  • THE KPM GROUP DC LLCRELMADA THERAPEUTICS, INC. · 2022 Q4$30K
    Filing ↗
  • THE KPM GROUP DC LLCRELMADA THERAPEUTICS, INC. · 2022 Q3$30K
    Filing ↗
  • THE KPM GROUP DC LLCRELMADA THERAPEUTICS, INC. · 2022 Q2$20K
    Filing ↗
  • THE KPM GROUP DC LLCRELMADA THERAPEUTICS, INC. · 2022 Q1$20K
    Filing ↗
  • THE KPM GROUP DC LLCRELMADA THERAPEUTICS, INC. · 2021 Q4$30K
    Filing ↗

Government Contracts

Federal awards to RELMADA THERAPEUTICS, INC. · USAspending

No federal contract awards found for RELMADA THERAPEUTICS, INC..

U.S. Patents

Recent USPTO applications naming RELMADA THERAPEUTICS, INC.

No USPTO patent applications found for RELMADA THERAPEUTICS, INC..

Annual Financials

From RLMD's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Operating income-$59.1M-$83.9M-$103.7M-$161.2M-$125.7M
Net income-$57.4M-$80.0M-$98.8M-$157.0M-$125.8M
Diluted EPS-$1.45-$2.65-$3.28-$5.30-$7.16
Operating cash flow-$45.8M-$51.8M-$51.7M-$103.8M-$91.9M
Cash and equivalents$3.5M$3.9M$4.1M$5.4M$44.4M
Total assets$94.0M$45.8M$97.6M$152.9M$223.3M
Total liabilities$7.5M$10.3M$12.2M$12.5M$15.1M
Shareholders' equity$86.5M$35.5M$85.4M$140.4M$208.3M

As RELMADA THERAPEUTICS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 19, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-4Reverse splitSep 30, 2019
  • 1-for-5Reverse splitAug 12, 2015

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 7.01, 9.01Reg FD disclosureNov 16, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureNov 12, 2026
    EDGAR ↗
  • 8-K · Items 8.01Other eventsSep 8, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureAug 6, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureJul 28, 2026
    EDGAR ↗
  • 8-K · Items 5.03, 5.07, 9.01Bylaw amendment · Shareholder voteMay 28, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureMay 12, 2026
    EDGAR ↗

About RELMADA THERAPEUTICS, INC.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersCORAL GABLES, FL
IncorporatedNV
Former namesCAMP NINE, INC.